Can MRKR sustain its Q3 earnings growth into 2025?

**Marker Therapeutics (MRKR) faces significant challenges in sustaining its Q3 earnings growth into 2025.** Here's why: 1. **Expected Loss in 2025**: Analysts predict that MRKR will report a loss of 22 cents per share in 2025, which suggests a continuation of the net loss trend observed in Q3 2024. 2. **No Q3 2025 Data**: There are no available financial data for MRKR in Q3 2025, which makes it difficult to assess the company's financial performance during that period. 3. **Financial Strain**: MRKR's financial statements show a loss from continuing operations before income taxes of $(10.681) million, and a net cash used in operating activities of $(10.910) million. These figures indicate a high level of financial strain that could hinder the company's ability to sustain growth. 4. **Revenue Growth**: While MRKR has seen a 99% increase in total revenues due to higher grant income, the company's revenue of $6.591 million is still significantly lower than the estimated revenue of $3.982 million for Q4 2024. This suggests that sustaining growth in revenue will be crucial for MRKR's future performance. 5. **Clinical and Regulatory Progress**: MRKR's focus on clinical trials and regulatory designations for its product candidates could potentially lead to future revenue streams. However, the outcomes of these efforts and their impact on earnings are uncertain. In conclusion, while MRKR has shown some positive signs in its financial performance and has potential for growth through its clinical and regulatory initiatives, the company's ability to sustain its Q3 earnings growth into 2025 is uncertain. The absence of Q3 2025 data, the expected loss per share, and the ongoing financial strain suggest that MRKR faces a challenging road ahead.